ATE553118T1 - Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz - Google Patents

Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz

Info

Publication number
ATE553118T1
ATE553118T1 AT01996547T AT01996547T ATE553118T1 AT E553118 T1 ATE553118 T1 AT E553118T1 AT 01996547 T AT01996547 T AT 01996547T AT 01996547 T AT01996547 T AT 01996547T AT E553118 T1 ATE553118 T1 AT E553118T1
Authority
AT
Austria
Prior art keywords
altered biological
biological persistence
clostridium toxin
modified clostridium
modified
Prior art date
Application number
AT01996547T
Other languages
English (en)
Inventor
Lance Steward
Athena Spanoyannis
Wei-Jen Lin
Kei Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22943921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE553118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE553118T1 publication Critical patent/ATE553118T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01996547T 2000-11-17 2001-11-16 Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz ATE553118T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24954000P 2000-11-17 2000-11-17
PCT/US2001/044030 WO2002040506A2 (en) 2000-11-17 2001-11-16 Modified clostridial neurotoxins with altered biological persistence

Publications (1)

Publication Number Publication Date
ATE553118T1 true ATE553118T1 (de) 2012-04-15

Family

ID=22943921

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996547T ATE553118T1 (de) 2000-11-17 2001-11-16 Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz

Country Status (7)

Country Link
US (1) US20020127247A1 (de)
EP (1) EP1334120B1 (de)
JP (1) JP2004536778A (de)
AT (1) ATE553118T1 (de)
AU (2) AU1985002A (de)
CA (2) CA2428136A1 (de)
WO (1) WO2002040506A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1729821B1 (de) * 2004-03-03 2013-07-17 ReVance Therapeutics, Inc. Zusammensetzungen und methoden zur topischen anwendung und transdermalen verabreichung von botulinus toxinen
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US8518414B2 (en) * 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
CA2694046C (en) * 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
RU2582266C2 (ru) * 2009-07-02 2016-04-20 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие сокращенную биологическую активность
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US10149893B2 (en) * 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN106103489B (zh) 2014-01-27 2020-10-02 分子模板公司 Mhc i类表位递送多肽
US9975929B2 (en) 2014-03-05 2018-05-22 Merz Pharma Gmbh & Co. Kgaa Recombinant clostridial neurotoxins with increased duration of effect
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
DK3242884T3 (da) * 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
WO2016180533A1 (en) * 2015-05-12 2016-11-17 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
PT3303373T (pt) * 2015-05-30 2020-07-14 Molecular Templates Inc Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11078472B2 (en) 2016-01-20 2021-08-03 Merz Pharma Gmbh & Co., Kgaa Recombinant clostridial neurotoxins with increased duration of effect
CA3010146A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
EP3290437A1 (de) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante clostridienneurotoxine mit verkürzter wirkungsdauer
EP3312193A1 (de) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante botulinumneurotoxine mit beschleunigter wirkung
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (de) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
EP3700919A1 (de) 2017-10-26 2020-09-02 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante botulinum-neurotoxine mit erhöhter wirkdauer
KR20200115479A (ko) 2018-01-29 2020-10-07 입센 바이오팜 리미티드 비-뉴런 snare-절단 보툴리눔 신경독소
JP6867452B2 (ja) * 2019-08-09 2021-04-28 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1996039166A1 (en) * 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
AU6326896A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Chemically-modified clostridiatoxin with improved properties
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
EP1409530A2 (de) * 2000-09-19 2004-04-21 Microbia, Inc. Modulation der herstellung von sekundärmetaboliten durch binukleäre zink-cluster-proteine

Also Published As

Publication number Publication date
JP2004536778A (ja) 2004-12-09
CA2632696A1 (en) 2002-05-23
CA2428136A1 (en) 2002-05-23
AU2002219850B2 (en) 2006-08-10
EP1334120A2 (de) 2003-08-13
WO2002040506A3 (en) 2003-03-27
WO2002040506A2 (en) 2002-05-23
US20020127247A1 (en) 2002-09-12
AU1985002A (en) 2002-05-27
EP1334120B1 (de) 2012-04-11

Similar Documents

Publication Publication Date Title
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
DE69937890D1 (de) Impfstoffe gegen neurotoxine von clostridium botulinum
DK1322324T3 (da) Fremgangsmåder til behandling af muskelskader
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE416191T1 (de) Abbaubare clostridientoxine
WO2002044199A3 (en) Neurotoxins with enhanced target specificity
ATE239491T1 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
WO2006138059A3 (en) Treatment of autoimmune disorders with a neurotoxin
TR200100728T2 (tr) Botulinum toksininin stabil sıvı formülasyonları
BR0312506A (pt) Composições transdérmicas de toxina botulìnica
WO2001054711A3 (en) Use of neurotoxins for treating diabetes
BRPI0412265A (pt) uso de calcitonina em osteoartrite
ATE229313T1 (de) Kosmetische zusammensetzung, die ein anionisches oder nichtionisches polymer und mindestens ein carboxysilikon enthält.
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
PT615751E (pt) Utilizacao de antagonistas de taquinina no tratamento da emese
HK1039622B (zh) 蘭抗生素
ATE334208T1 (de) Menschliche proteasen und für diese kodierende polynukleotide
WO2005016232A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ATE301194T1 (de) Beta-defensine
AR020141A1 (es) Toxinas y genes pesticidas de cepas de bacillus laterosporus
ATE355378T1 (de) Menschliche phospholipasen und diese kodierende polynukleotide
ATE366315T1 (de) Menschliche enzyme und dafür kodierende polynukleotide
DE60119757D1 (de) Menschliche ionenaustauschproteine und dafür kodierende polynukleotiden
DE60118703D1 (de) Menschliche neurexin-ähnliche proteine und dafür kodierende polynukleotide